1. Home
  2. VTRS

VTRS

Viatris Inc.

Logo Viatris Inc.

Health Care

Medicinal Chemicals and Botanical Products

Nasdaq

as 04-22-2024 3:30pm EST

$
-
-
.
-
-
+$
-
.
-
-
+
-
.
-
-
%

Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. Remaining 60% of sales is derived from its portfolio of legacy products which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.

Founded: N/A Country:
United States
United States
Employees: N/A City: CANONSBURG
Market Cap: 13.4B IPO Year: N/A
Target Price: $11.00 AVG Volume (30 days): 8.9M
Analyst Decision: Sell Number of Analysts: 3
Dividend Yield: 4.27% Dividend Payout Frequency: Quarterly
EPS: 0.05 EPS Growth: -97.08
52 Week Low/High: $8.74 - $13.62 Next Earning Date: 05-09-2024
Revenue: $15,426,900,000 Revenue Growth: -5.14%
Revenue Growth (this year): 1.7% Revenue Growth (next year): -2.04%

Share on Social Networks:

Stock Insider Trading Activity of Viatris Inc. (VTRS)

Name Ticker Relationship Date Transaction Cost Per Share Shares Total Value Securities Owned After Transaction(s) SEC Form 4
Lyons Dillon JoEllen VTRS Director Mar 3 '24 Sell $12.36 20,000 $247,200.00 58,714 SEC Form 4